JPRN-jRCT2080224615已完成1 期
An Open-label, One-sequence Crossover Study of Solithromycin to Evaluate the Effects on the Pharmacokinetics of Metformin Hydrochloride in Healthy Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- All
入选标准
- •1. Japanese healthy subjects between 20 and 55 years of age
- •2. BMI between 18.0 and 30.0 kg/ m2
- •3. Understand the requirements of the study and voluntarily consent to participate in the study
排除标准
- •1. Have a history or presence of clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results
- •2. Have a history of allergy to macrolide antibiotics or biguanides
研究者
相似试验
已完成
1 期
An Open-label, One-sequence Crossover Study of Solithromycin to Evaluate the Effects on the Pharmacokinetics of Rosuvastatin Calcium in Healthy Adult Subjects-JPRN-jRCT2080224614FUJIFILM Toyama Chemical Co., Ltd.14
未知
1 期
DS-8500a atorvastatin DDI studyHealthy volunteersJPRN-jRCT2080222826DAIICHISANKYO Co.,Ltd.28
进行中（未招募）
1 期
An Open-label, One-sequence Crossover Study of Favipiravir to Evaluate the Effects on the Pharmacokinetics of Triazolam/Metformin Hydrochloride in Healthy Adult Subjectssevere fever with thrombocytopenia syndromeJPRN-jRCT2031220735Sakurai Tsutomu24
招募中
Unknown
A single-center open-label crossover study of the clinical utility and safety of the BV-UFC system of the DCS-200Si dialysis monitorPatients undergoing hemodialysishemodialysisD006435JPRN-jRCT1062230034Hamada Shintaro20
进行中（未招募）
不适用
An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency.AGHD Adult Growth Hormone DeficiencyEUCTR2005-001658-25-BEPfizer Global Research and Development8